Abstract: A polyelectrolyte coating comprises at least one polycationic layer consisting of at least one polyarginine as herein defined and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit. Also disclosed is a method of preventing a bacterial infection in an individual.

Abstract: Embodiments of the present disclosure relate to methods of screening and optionally designing compounds as inhibitors of Mfd (Mutation Frequency Decline), such compounds being useful for the treatment of bacterial infections. Embodiments of the methods include culturing pathogenic bacteria expressing functional Mfd with various concentrations of 1 mM or less, incubating the cultures with and without nitric oxide stress conditions, evaluating bacterial survival in each of the cultures, and calculating the concentration of the molecule required to decrease by 50% the survival rate of the bacteria (IC50) by comparing the cfu of the untreated cultures and cultures following nitric oxide stress.

Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.

Abstract: The present invention relates to the cosmetic or pharmaceutical use for a composition comprising a salicylic or nicotinic acid derivative inhibiting chemokines, for preventing or treating chronic internal and/or external inflammatory conditions.

Abstract: The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.

Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.

Abstract: This invention relates to a micro-device for detecting volatile compounds comprising: an input (E) and an output (S); collection means (2) for taking a gas sample containing at least one compound to be detected; sampling means enabling a gas volume of 100 mL or less to be sampled, arranged after the collection means; injection means (3) of said gas sample; separation means (5) of the compound to be detected in the gas sample; compound detection means (6); and a gas circulation circuit (1) located downstream of the collection means and passing through the sampling means, injection means (3), separation means (5) and detection means (6); characterized in that the gas circulation circuit (1) has a volume of between 0.2 cm3 and 2.0 cm3.

Abstract: The present invention relates to disintegratable core/shell silica particles encapsulating a bioactive macromolecule or bioactive macromolecule cluster in an active conformation, a method for producing the same, and uses thereof.

Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.

Abstract: The present invention is in the field of surfactants to extract a platinum group metal or gold, in particular palladium, from organic compositions. In particular, the invention concerns the use of surfactants to back-extract a platinum group metal or gold, in particular palladium, from organic compositions further comprising an extractant of said platinum group metal or gold, in particular palladium from an aqueous solution.

Abstract: A compound is provided which has dual emission properties and which is useful in light devices, and which has formula (I): wherein: A represents an electron-withdrawing group; D represents an electron-donating group; X is selected from the group consisting of: O, S and NR, wherein R is selected from the group consisting of: H, an alkyl group preferably comprising from 1 to 20 carbon atoms, an aryl group preferably comprising from 6 to 22 carbon atoms, and a heteroaryl group; n is an integer from 1 to 4; m is an integer from 1 to 6; and represents a condensed bicyclic aromatic radical comprising from 6 to 22 carbon atoms, and from 1 to 3 heteroatom(s) selected from the group consisting of: N, S and O; the OH group being in ortho position of the condensed bicyclic aromatic radical relative to the radical.

Abstract: An optical guide for a near-eye display device includes a first guide element having a light input zone and a second guide element having an output zone. The first guide element is superimposed on the second guide element. The optical guide also includes an optical coupling system between the first guide element and the second guide element, and the first and second guide elements have, on the first part of their length, a mutual spacing so as to delimit a thin layer of air between said guide elements extending between a first longitudinal end of the guide elements and the optical coupling system. The optical coupling system, located at a second longitudinal end of the first and second guide elements, includes a single-piece portion of the guide elements, associated with an optical reflection member to propagate the beams of light from the input zone toward the output zone.

Abstract: Disclosed is an inflatable balloon for medical use, intended to be inserted deflated into a human or animal body cavity and then inflated once inside this cavity so as to apply pressure against the cavity. The inflatable balloon includes a balloon body, the wall of which is made from a flexible inflatable material, the balloon body having a generally elongated shape with a proximal inflation end and a distal positioning end at the back of the cavity. It further includes an inflation opening formed in the proximal end through which a fluid is introduced into the balloon body so as to inflate it under pressure. The wall of the balloon body locally has an elongated portion called the sole that is stiffer than the rest of the wall, this sole extending from the proximal end to the distal end.

Abstract: A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

Abstract: RNA aptamers are disclosed with distinct fluorescent properties, fluorophore binding affinities, and salt dependence. Also disclosed are corresponding fluorophores, with selected fluorophores evidencing high cellular permeability. The aptamer's high fluorophore affinities, the high brightness of the bound complexes, and their thermal and salt stability, provide distinct aspects of the disclosed aptamers.

Abstract: The application pertains to the field of biomaterials and their use, in particular for the production of implants to support the growth and recovery of biological tissues. More particularly, a fibrous polymer material is described comprising a first layer of aligned fibroin fiber, a second layer of fibroin fibers, wherein the fibroin fibers are randomly oriented within said second layer, a third layer of aligned fibroin fibers; and polymer scaffolds comprising thereof.

Abstract: A master interface device for remotely controlling at least one instrument mounted in an endoscope. The device includes at least one control handle device in the form of a subassembly able to be manipulated in the same degrees of freedom as the associated control instrument. The control device includes on the one hand a gripping and manoeuvring shaft, designed for gripping with the whole hand by the operator, and on the other hand a mounting bracket supporting said shaft. Translation and pivoting of the bracket controls respectively translation and rotation around itself of the associated instrument, and the pivoting of the shaft relative to the bracket controls the bending of the end of the instrument concerned.

Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.

Abstract: The present invention relates to hydroxychloroquine analogues having an activity superior to that of hydroxychloroquine but free from retinal cytotoxicity of formula (I), their pharmaceutically acceptable salts, solvates or hydrates: their method of preparation and their use in the treatment of lupus erythematosus.

Abstract: A system for an automatic multimodal real-time tracking of moving instruments for image plane alignment inside an MRI scanner includes: an MRI scanner, an MRI multi-plane pulse sequence generating unit allowing to interactively modify the position and orientation of one or several image planes in real-time, one or several external optical sensors with high frame rate, preferably a RGB-D sensor or other similar camera system like a stereovision systems, a multimodal marker including at least one MR visible feature and one visual feature able to be tracked by both the MRI scanner and the at least one external optical sensor, a computer for processing in real-time images from both MRI and optical sensor to fuse the detected marker position and orientation or pose from both modalities, and predict the next image plane position and orientation based on the estimated motion of the moving marker.